Clinical Trial Update: Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating GTx-024 for muscle wasting in first-line platinum-treated non-small cell lung cancer patients has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Muscle Wasting
• Non-small Cell Lung Cancer

Drugs mentioned

• GTx-024

Snippet

Sponsor: GTx | Conditions: Muscle Wasting, Non-Small Cell Lung Cancer | Phase 3 | Status: COMPLETED | Results posted: 2020-11-09